Top

Published in:

Open Access 01-03-2019 | Nephrology - Original Paper

Relationship between plasma levels of sclerostin, calcium–phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients

Authors: Barbara Pietrzyk, Katarzyna Wyskida, Joanna Ficek, Aureliusz Kolonko, Rafał Ficek, Andrzej Więcek, Magdalena Olszanecka-Glinianowicz, Jerzy Chudek

Published in: International Urology and Nephrology | Issue 3/2019

Abstract

Purpose

Data concerning the relation between increased levels of circulating sclerostin (a physiological inhibitor of bone formation) and bone turnover in patients with chronic renal failure (CRF) are limited. Therefore, the aim of this study was to evaluate associations between plasma sclerostin levels and calcium–phosphate disturbances, markers of bone turnover as well as inflammation in haemodialysis (HD) patients.

Methods

In plasma samples obtained in 150 stable HD patients (92 men) aged 40–70 years, levels of sclerostin, fibroblast growth factor (cFGF23), osteocalcin, the N-terminal propeptide of type I procollagen, C-terminal telopeptide of the alpha chain of type I collagen (β-CTx), and inflammatory markers (IL-6 and TNF-α) in addition to routine parameters (calcium, phosphorus, parathyroid hormone—iPTH, 25-OH-D, alkaline phosphatase) were measured.

Results

Plasma sclerostin concentrations were significantly higher in HD men than women (2.61 vs. 1.88 ng/mL, p < 0.01). Patients with sclerostin levels above median were characterized by lower iPTH and IL-6, but higher cFGF23 and TNF-α (significantly only in men) concentrations. Plasma sclerostin concentration positively correlated with serum 25-OH-D (τ = 0.204), phosphorus (τ = 0.1482), and TNF-α (τ = 0.183) and inversely with iPTH (τ = − 0.255), alkaline phosphatase (τ = − 0.203), IL-6 (τ =− 0.201), and β-CTx (τ = − 0.099) levels. In multivariate regression analysis, variability of sclerostin levels was explained by sex and 25-OH-D and phosphorus levels.

Conclusions

Increased circulating sclerostin levels seem to reflect slower bone turnover in HD patients. Low levels of sclerostin are associated with vitamin D deficiency and good phosphates alignment.

Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL (2010) Sclerostin: Current knowledge and future perspectives. Calcif Tissue Int 87:99–107 1CrossRefPubMedPubMedCentral

Khosla S, Westendorf JJ, Oursler MJ (2008) Building bone to reverse osteoporosis and repair fractures. J Clin Invest 118:421–428CrossRefPubMedPubMedCentral

Cianferotti L, Demay MB (2007) VDR-mediated inhibition of DKK1 and SFRP2 suppresses adipogenic differentiation of murine bone marrow stromal cells. J Cell Biochem 101:80–88CrossRefPubMed

Carvallo L, Henríquez B, Paredes R et al (2008) 1alpha,25-dihydroxy vitamin D3-enhanced expression of the osteocalcin gene involves increased promoter occupancy of basal transcription regulators and gradual recruitment of the 1-alpha,25-dihydroxy vitamin D3 receptor-SRC-1 coactivator complex. J Cell Physiol 214:740–749CrossRefPubMed

Lu Y, Yuan B, Qin C et al (2011) The biological function of DMP-1 in osteocyte maturation is mediated by its 57-kDa C-terminal fragment. J Bone Miner Res 26:331–340CrossRefPubMed

Gregson CL, Poole KE, McCloskey et al (2014) Elevated circulating Sclerostin concentrations in individuals with high bone mass, with and without LRP5 mutations. J Clin Endocrinol Metab 99: 2897–2907. https://doi.org/10.1210/jc.2013-3958 CrossRefPubMedPubMedCentral

Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH (2011) Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res 26:2812–2822CrossRefPubMed

Moe SM, Drueke TB, Block GA, Cannata-Andia JB et al (2009) KDIGO Clinical Practice Guidelines for the Diagnosis, Evaluation, Prevention and Treatment of Chronic Kidney Disease—Mineral and Bone Disorder (CKD-MBD); Kidney Disease Improving Global Outcomes (KDIGO) CKD-MBD, Work Group Am. Kidney Int Suppl (113): S1–S130. https://doi.org/10.1038/ki.2009.188

Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R (2014) National Osteoporosis Foundation: Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int 25:2359–2381CrossRefPubMedPubMedCentral

10.

Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche HH (2011) Sclerostin and Dickkopf-1in renal osteodystrophy. Clin J Am Soc Nephrol 6: 877–882. https://doi.org/10.2215/CJN.06550810 CrossRefPubMedPubMedCentral

11.

Rodriguez M, Cañadillas S, Lopez I, Aguilera-Tejero E, Almaden Y (2006) Regulation of parathyroid function in chronic renal failure. J Bone Miner Metab 24:164–168CrossRefPubMed

12.

Almroth G, Lönn J, Uhlin F, Brudin L, Andersson B, Hahn-Zoric M (2015) Sclerostin, TNF-alpha and Interleukin-18 Correlate and are Together with Klotho Related to Other Growth Factors and Cytokines in Haemodialysis Patients. Scand J Immunol 83:58–63CrossRef

13.

Ficek J, Wyskida K, Ficek R et al (2017) Relationship between plasma levels of zonulin, bacterial lipopolysaccharides, D-lactate and markers of inflammation in haemodialysis patients. Int Urol Nephrol 49:717–725. https://doi.org/10.1007/s11255-016-1495-5 CrossRefPubMedPubMedCentral

14.

Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser W, Goldsmith D, Hampson G (2012) Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 90:473–480CrossRefPubMed

15.

Bonani M, Rodriguez D, Fehr T, Mohebbi N, Brockmann J, Blum M, Graf N, Frey D, Wuthrich RP (2014) Sclerostin blood levels before and after kidney transplantation. Kidney Blood Press Res 39:230–239CrossRefPubMed

16.

de Oliveira RA, Barreto FC, Mendes M, dos Reis LM, Castro JH, Britto ZM, Marques ID, Carvalho AB, Moysés RM, Jorgetti V (2015) Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease. Kidney Int 87:1039–1045. https://doi.org/10.1038/ki.2014.372 CrossRefPubMed

17.

Jin S, Zhu M, Yan J, Fang Y, Lu R, Zhang W, Zhang Q, Lu J, Qi C, Shao X, Zhang H, Jiang R, Ni Z (2016) Serum sclerostin level might be a potential biomarker for arterial stiffness in prevalent hemodialysis patients. Biomark Med 10:689–699CrossRefPubMed

18.

Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling - Hampton K (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267–6276CrossRefPubMedPubMedCentral

19.

Behets GJ, Viaene L, Meijers B, Blocki F, Brandenburg VM, Verhulst A, D’Haese PC, Evenepoel P (2017) Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD. PLoS ONE 12: e0176411. https://doi.org/10.1371/journal.pone.0176411. eCollection 2017CrossRefPubMedPubMedCentral

20.

Delanaye P, Krzesinski JM, Warling X, Moonen M, Smelten N, Medart L et al (2014) Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron Clin Pract 128:127–134. https://doi.org/10.1159/000366449 CrossRefPubMed

21.

Ishimura E, Okuno S, Ichii M, Norimine K, Yamakawa T, Shoji S et al (2014) Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients. J Clin Endocrinol Metab 99: 4315–4320. https://doi.org/10.1210/jc.2014-2372 CrossRefPubMed

22.

Cejka D, Jager-Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider DG et al (2012) Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 27: 226–230. https://doi.org/10.1093/ndt/gfr270 CrossRefPubMed

23.

Keller H, Kneissel M (2005) SOST is a target gene for PTH in bone. Bone 37:148–158CrossRefPubMed

24.

Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O’Brien CA, Manolagas SC, Jilka RL (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577–4583CrossRefPubMed

25.

Wijenayaka AR, Yang D, Prideaux M, Ito N, Kogawa M, Anderson PH et al (2015) 1a,25-dihydroxyvitamin D3 stimulates human SOST gene expression and sclerostin secretion. Mol Cell Endocrinol 413:1e11CrossRef

26.

Torino C, Pizzini P, Cutrupi S, Tripepi G, Mallamaci F, Thadhani R, Zoccali C (2017) Active vitamin D treatment in CKD patients raises serum sclerostin and this effect is modified by circulating pentosidine levels. Nutr Metab Cardiovasc Dis 27:260–266CrossRefPubMed

27.

Yadav AK, Kumar V, Banerjee D, Gupta KL, Jha V (2018) Effect of vitamin D supplementation on serum sclerostin levels in chronic kidney disease. J Steroid Biochem Mol Biol 180:15–18. https://doi.org/10.1016/j.jsbmb.2018.01.007 CrossRefPubMed

28.

Acıbucu F, Dokmetas HS, Acıbucu DO, Kılıclı F, Aydemir M, Cakmak E (2017) Effect of Vitamin D Treatment on Serum Sclerostin Level. Exp Clin Endocrinol Diabetes 125:634–637CrossRefPubMed

29.

Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H et al (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370e8CrossRef

30.

Bożentowicz-Wikarek M, Owczarek A, Kocełak P, Olszanecka-Glinianowicz M, Więcek A, Chudek J (2016) C-terminal to intact fibroblast growth factor 23 ratio in relation to estimated glomerular filtration rate in elderly population. Kidney Blood Press Res 41:519–526CrossRefPubMed

31.

Asamiya Y, Yajima A, Shimizu S, Otsubo S, Tsuchiya K, Nitta K (2015) Associations between the levels of sclerostin, phosphate, and fibroblast growth factor-23 and treatment with vitamin D in hemodialysis patients with low intact PTH level. Osteoporos Int 26:1017–1028CrossRefPubMed

Title: Relationship between plasma levels of sclerostin, calcium–phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients
Authors: Barbara Pietrzyk
Katarzyna Wyskida
Joanna Ficek
Aureliusz Kolonko
Rafał Ficek
Andrzej Więcek
Magdalena Olszanecka-Glinianowicz
Jerzy Chudek
Publication date: 01-03-2019
Publisher: Springer Netherlands
Published in: International Urology and Nephrology / Issue 3/2019
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-018-2050-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Relationship between plasma levels of sclerostin, calcium–phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2019

Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease

The safety of extracorporeal shock wave lithotripsy: an undervalued issue

Whole mount histopathological correlation with prostate MRI in Grade I and II prostatectomy patients

Laparoendoscopic single-site nephrectomy with the aid of intraabdominal retractors

Socioeconomic status and mortality among dialysis patients: a systematic review and meta-analysis

Association of neutrophil-to-lymphocyte ratio with early renal dysfunction and albuminuria among diabetic patients

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page